Table 1.
Characteristic | Value | Percentage |
---|---|---|
Median age at study entry (years) | 64 | |
IQR | 57–71 | |
Sex | ||
Female | 42 | 37% |
Male | 70 | 63% |
Site of the primary tumor | ||
Rectum | 50 | 45% |
Rectosigmoid junction | 2 | 1.8% |
Sigmoid colon | 25 | 22% |
Splenic flexure | 4 | 3.6% |
Transverse colon | 6 | 5.4% |
Hepatic flexure | 1 | 0.9% |
Ascending colon | 7 | 6.3% |
Cecum | 8 | 7.1% |
Appendix | 1 | 0.9% |
Two sites | 3 | 2.7% |
Unknown | 5 | 4.5% |
Tumor stage at study entry* | ||
Stage 0 | 3 | 2.7% |
Stage I | 9 | 8% |
Stage II | 11 | 9.8% |
Stage III | 17 | 15% |
Stage IV | 72 | 64% |
Progression of tumor at study entry | ||
Localized | 40 | 36% |
Distant metastasis | 72 | 64% |
Anti-VEGF-A treatment from study entry | ||
Bevacizumab treatment | 49 | 44% |
Study patient optional bevacizumab treatment | 2 | 1.8% |
Categorical variables are described with absolute numbers and percentages. Age is described as median with IQR.
For staging UICC staging was used (stage Ia and Ib are summarized as stage I; stage 0 is defined as ypT0pN0M0, R0 - these are patients with rectum carcinoma, who received presurgical radiotherapy).